Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. / Cele, Sandile; Jackson, Laurelle; Khoury, David S.; Khan, Khadija; Moyo-Gwete, Thandeka; Tegally, Houriiyah; San, James Emmanuel; Cromer, Deborah; Scheepers, Cathrine; Amoako, Daniel G.; Karim, Farina; Bernstein, Mallory; Lustig, Gila; Archary, Derseree; Smith, Muneerah; Ganga, Yashica; Jule, Zesuliwe; Reedoy, Kajal; Hwa, Shi Hsia; Giandhari, Jennifer; Blackburn, Jonathan M.; Gosnell, Bernadett I.; Abdool Karim, Salim S.; Hanekom, Willem; Davies, Mary Ann; Hsiao, Marvin; Martin, Darren; Mlisana, Koleka; Wibmer, Constantinos Kurt; Williamson, Carolyn; York, Denis; Harrichandparsad, Rohen; Herbst, Kobus; Jeena, Prakash; Khoza, Thandeka; Kløverpris, Henrik; Leslie, Alasdair; Madansein, Rajhmun; Magula, Nombulelo; Manickchund, Nithendra; Marakalala, Mohlopheni; Mazibuko, Matilda; Moshabela, Mosa; Mthabela, Ntombifuthi; Naidoo, Kogie; Ndhlovu, Zaza; Ndung’u, Thumbi; Ngcobo, Nokuthula; Nyamande, Kennedy; Patel, Vinod; NGS-SA; COMMIT-KZN Team.
In: Nature, Vol. 602, No. 7898, 2022, p. 654-656.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
AU - Cele, Sandile
AU - Jackson, Laurelle
AU - Khoury, David S.
AU - Khan, Khadija
AU - Moyo-Gwete, Thandeka
AU - Tegally, Houriiyah
AU - San, James Emmanuel
AU - Cromer, Deborah
AU - Scheepers, Cathrine
AU - Amoako, Daniel G.
AU - Karim, Farina
AU - Bernstein, Mallory
AU - Lustig, Gila
AU - Archary, Derseree
AU - Smith, Muneerah
AU - Ganga, Yashica
AU - Jule, Zesuliwe
AU - Reedoy, Kajal
AU - Hwa, Shi Hsia
AU - Giandhari, Jennifer
AU - Blackburn, Jonathan M.
AU - Gosnell, Bernadett I.
AU - Abdool Karim, Salim S.
AU - Hanekom, Willem
AU - Davies, Mary Ann
AU - Hsiao, Marvin
AU - Martin, Darren
AU - Mlisana, Koleka
AU - Wibmer, Constantinos Kurt
AU - Williamson, Carolyn
AU - York, Denis
AU - Harrichandparsad, Rohen
AU - Herbst, Kobus
AU - Jeena, Prakash
AU - Khoza, Thandeka
AU - Kløverpris, Henrik
AU - Leslie, Alasdair
AU - Madansein, Rajhmun
AU - Magula, Nombulelo
AU - Manickchund, Nithendra
AU - Marakalala, Mohlopheni
AU - Mazibuko, Matilda
AU - Moshabela, Mosa
AU - Mthabela, Ntombifuthi
AU - Naidoo, Kogie
AU - Ndhlovu, Zaza
AU - Ndung’u, Thumbi
AU - Ngcobo, Nokuthula
AU - Nyamande, Kennedy
AU - Patel, Vinod
AU - NGS-SA
AU - COMMIT-KZN Team
N1 - Publisher Copyright: © 2021, The Author(s).
PY - 2022
Y1 - 2022
N2 - The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections1. Here we investigated Omicron escape from neutralization by antibodies from South African individuals vaccinated with Pfizer BNT162b2. We used blood samples taken soon after vaccination from individuals who were vaccinated and previously infected with SARS-CoV-2 or vaccinated with no evidence of previous infection. We isolated and sequence-confirmed live Omicron virus from an infected person and observed that Omicron requires the angiotensin-converting enzyme 2 (ACE2) receptor to infect cells. We compared plasma neutralization of Omicron relative to an ancestral SARS-CoV-2 strain and found that neutralization of ancestral virus was much higher in infected and vaccinated individuals compared with the vaccinated-only participants. However, both groups showed a 22-fold reduction in vaccine-elicited neutralization by the Omicron variant. Participants who were vaccinated and had previously been infected exhibited residual neutralization of Omicron similar to the level of neutralization of the ancestral virus observed in the vaccination-only group. These data support the notion that reasonable protection against Omicron may be maintained using vaccination approaches.
AB - The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections1. Here we investigated Omicron escape from neutralization by antibodies from South African individuals vaccinated with Pfizer BNT162b2. We used blood samples taken soon after vaccination from individuals who were vaccinated and previously infected with SARS-CoV-2 or vaccinated with no evidence of previous infection. We isolated and sequence-confirmed live Omicron virus from an infected person and observed that Omicron requires the angiotensin-converting enzyme 2 (ACE2) receptor to infect cells. We compared plasma neutralization of Omicron relative to an ancestral SARS-CoV-2 strain and found that neutralization of ancestral virus was much higher in infected and vaccinated individuals compared with the vaccinated-only participants. However, both groups showed a 22-fold reduction in vaccine-elicited neutralization by the Omicron variant. Participants who were vaccinated and had previously been infected exhibited residual neutralization of Omicron similar to the level of neutralization of the ancestral virus observed in the vaccination-only group. These data support the notion that reasonable protection against Omicron may be maintained using vaccination approaches.
U2 - 10.1038/s41586-021-04387-1
DO - 10.1038/s41586-021-04387-1
M3 - Journal article
C2 - 35016196
AN - SCOPUS:85122689652
VL - 602
SP - 654
EP - 656
JO - Nature
JF - Nature
SN - 0028-0836
IS - 7898
ER -
ID: 305717771